ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ReCode Therapeutics to Present at September Investor Conferences

ReCode Therapeutics, a clinical-stage company powering the next wave of genetic medicines, today announced that Company management will participate in the following upcoming investor conferences in September 2023:

Morgan Stanley Global Healthcare Conference:

Format: Company Presentation

Date: September 12, 2023

Time: 12:55 p.m. ET

Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics

Location: New York, NY

Jefferies Cell & Genetic Medicine Summit

Format: Company Presentation

Date: September 26, 2023

Time: 10:30 a.m. ET

Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics

Location: New York, NY

BMO Biopharma Spotlight Series: Latest Advances in Genome/Epigenome Editing

Format: Panel Discussion - Novel Approaches in Gene Editing and Delivery

Date: September 26, 2023

Time: 2:30 p.m. ET

Presenter: Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics

Location: Virtual

About ReCode Therapeutics

ReCode Therapeutics is a clinical-stage company powering the next wave of genetic medicines. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. In 2022, ReCode was named among Fierce Biotech’s “Fierce 15” as one of the most promising early-stage biotechnology companies in the industry and was described by Nature as one of the “Seven Technologies to Watch in 2022” for its SORT LNP platform. For more information, visit www.recodetx.com and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  242.71
-3.76 (-1.53%)
AAPL  260.29
+0.04 (0.02%)
AMD  220.96
+13.27 (6.39%)
BAC  54.65
-0.54 (-0.99%)
GOOG  339.05
+6.32 (1.90%)
META  628.70
-13.27 (-2.07%)
MSFT  468.78
-8.40 (-1.76%)
NVDA  185.12
+0.18 (0.10%)
ORCL  201.51
-3.17 (-1.55%)
TSLA  447.85
-1.11 (-0.25%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.